Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, Oridis to Offer Protein-Biomarker Services

NEW YORK (GenomeWeb News) — Expression Pathology has formed an alliance with the Austrian company Oridis Biomed to offer proteomic tissue-analysis services for protein biomarker research, the companies said today.
Under the agreement, both companies will be able to offer the collaborative research services to clients in the drug-development, medical-diagnostic, and academic spheres.
The collaboration will use Expression Pathology’s Liquid Tissue and Director mass spectrometry and proteomics technologies, along with Oridis’ Tissomics high-throughput platform, and its access to formalin-fixed tissue samples.
Expression Pathology CEO Casey Eitner said the alliance will help drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity.
Oridis CEO Peter Hecht said the collaboration will allow companies to use mass spec and other pathology techniques to “mine tissue archives with detailed clinical outcomes and pathology data."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.